# Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

> **NCT06049212** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 30 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer
- Solid Tumors
- Programmed Cell Death-1 (PD1, PD-1)
- Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
- Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)

## Interventions

- **BIOLOGICAL:** Sacituzumab tirumotecan
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Supportive care measures

## Key facts

- **NCT ID:** NCT06049212
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-26
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-01-29
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06049212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06049212, "Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06049212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*